U.S. Markets closed

Celsion Corporation (CLSN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.50-0.06 (-3.85%)
At close: 4:00PM EDT
People also watch

Celsion Corporation

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States

Full Time Employees19

Key Executives

Mr. Michael H. TardugnoExec. Chairman, Chief Exec. Officer and Pres539.25kN/A66
Mr. Jeffrey W. Church CPACFO, Sr. VP of Corp. Strategy & IR and Corp. Sec.354.04kN/A60
Dr. Khursheed Anwer Ph.D., M.B.A.Chief Scientific Officer and Exec. VP315.32kN/A57
Dr. Nicholas Borys M.D.Chief Medical Officer and Sr. VP381.83kN/A58
Mr. Timothy J. Tumminello CPAChief Accounting Officer and ControllerN/AN/A59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Corporate Governance

Celsion Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.